Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

889 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations.
Cardona AF, Rojas L, Wills B, Arrieta O, Carranza H, Vargas C, Otero J, Corrales-Rodriguez L, Martín C, Reguart N, Archila P, Rodríguez J, Cuello M, Ortíz C, Franco S, Rolfo C, Rosell R, on behalf of the CLICaP. Cardona AF, et al. Among authors: otero j. Oncotarget. 2016 Sep 19;7(42):68933-68942. doi: 10.18632/oncotarget.12112. Oncotarget. 2016. PMID: 27926478 Free PMC article.
Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab.
Wills B, Cardona AF, Rojas L, Ruiz-Patiño A, Arrieta O, Reguart N, Carranza H, Vargas C, Otero J, Corrales L, Martín C, Cuello M, Pino LE, Rolfo C, Rosell R, Zatarain-Barrón ZL; Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). Wills B, et al. Among authors: otero j. Anticancer Res. 2017 Nov;37(11):6429-6436. doi: 10.21873/anticanres.12097. Anticancer Res. 2017. PMID: 29061829
Real-World Treatment Patterns, Survival, and Prediction of CNS Progression in ALK-Positive Non-Small-Cell Lung Cancer Patients Treated with First-Line Crizotinib in Latin America Oncology Practices.
Martín C, Cardona AF, Zatarain-Barrón ZL, Ruiz-Patiño A, Castillo O, Oblitas G, Corrales L, Lupinacci L, Pérez MA, Rojas L, González L, Chirinos L, Ortíz C, Lema M, Vargas C, Puparelli C, Carranza H, Otero J, Arrieta O. Martín C, et al. Among authors: otero j. Oncology. 2018;94(5):297-305. doi: 10.1159/000486862. Epub 2018 Mar 6. Oncology. 2018. PMID: 29510386
EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP).
Ruiz-Patiño A, Castro CD, Ricaurte LM, Cardona AF, Rojas L, Zatarain-Barrón ZL, Wills B, Reguart N, Carranza H, Vargas C, Otero J, Corrales L, Martín C, Archila P, Rodriguez J, Avila J, Bravo M, Pino LE, Rosell R, Arrieta O; Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). Ruiz-Patiño A, et al. Among authors: otero j. Target Oncol. 2018 Oct;13(5):621-629. doi: 10.1007/s11523-018-0594-x. Target Oncol. 2018. PMID: 30284706
EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP).
Cardona AF, Rojas L, Zatarain-Barrón ZL, Freitas HC, Granados ST, Castillo O, Oblitas G, Corrales L, Castro CD, Ruiz-Patiño A, Martín C, Pérez MA, González L, Chirinos L, Vargas C, Carranza H, Otero J, Rodriguez J, Rodriguez J, Archila P, Lema M, Acosta Madiedo J, Karachaliu N, Wills B, Pino LE, de Lima V, Rosell R, Arrieta O; CLICaP. Cardona AF, et al. Among authors: otero j. Lung Cancer. 2018 Nov;125:265-272. doi: 10.1016/j.lungcan.2018.10.007. Epub 2018 Oct 9. Lung Cancer. 2018. PMID: 30429031
Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP).
Ruiz-Patiño A, Arrieta O, Cardona AF, Martín C, Raez LE, Zatarain-Barrón ZL, Barrón F, Ricaurte L, Bravo-Garzón MA, Mas L, Corrales L, Rojas L, Lupinacci L, Perazzo F, Bas C, Carranza O, Puparelli C, Rizzo M, Ruiz R, Rolfo C, Archila P, Rodríguez J, Sotelo C, Vargas C, Carranza H, Otero J, Pino LE, Ortíz C, Laguado P, Rosell R; CLICaP. Ruiz-Patiño A, et al. Among authors: otero j. Thorac Cancer. 2020 Feb;11(2):353-361. doi: 10.1111/1759-7714.13272. Epub 2019 Dec 12. Thorac Cancer. 2020. PMID: 31828967 Free PMC article.
Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP).
Ruiz-Patiño A, Barrón F, Cardona AF, Corrales L, Mas L, Martín C, Zatarain-Barrón ZL, Recondo G, Ricaurte L, Rojas L, Archila P, Rodríguez J, Sotelo C, Viola L, Vargas C, Carranza H, Otero J, Pino LE, Rolfo C, Rosell R, Arrieta O; CLICaP. Ruiz-Patiño A, et al. Among authors: otero j. Thorac Cancer. 2020 Sep;11(9):2552-2560. doi: 10.1111/1759-7714.13573. Epub 2020 Jul 24. Thorac Cancer. 2020. PMID: 32705787 Free PMC article.
EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP).
Cardona AF, Ordóñez-Reyes C, Ruiz-Patiño A, Garcia-Robledo JE, Barron LZ, Recondo G, Rojas L, Corrales L, Martín C, Barrón F, Sotelo C, Rodríguez J, Ricaurte L, Rolfo C, Ávila J, Mayorga D, Archila P, Otero J, Mas L, Bermudez M, Gamez T, Carranza H, Vargas C, Rosell R, Arrieta O. Cardona AF, et al. Among authors: otero j. JCO Precis Oncol. 2021 Nov;5:839-848. doi: 10.1200/PO.20.00404. JCO Precis Oncol. 2021. PMID: 34994616
Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP).
Cardona AF, Ruiz-Patiño A, Recondo G, Martín C, Raez L, Samtani S, Minata JN, Blaquier JB, Enrico D, Burotto M, Ordóñez-Reyes C, Chamorro DF, Garcia-Robledo JE, Corrales L, Zatarain-Barrón ZL, Más L, Sotelo C, Ricaurte L, Santoyo N, Cuello M, Mejía S, Jaller E, Vargas C, Carranza H, Otero J, Rodríguez J, Archila P, Bermudez M, Gamez T, Cordeiro de Lima V, Freitas H, Russo A, Polo C, Malapelle U, Perez DM, Rolfo C, Viola L, Rosell R, Arrieta O. Cardona AF, et al. Among authors: otero j. Clin Lung Cancer. 2022 Sep;23(6):522-531. doi: 10.1016/j.cllc.2022.06.001. Epub 2022 Jun 6. Clin Lung Cancer. 2022. PMID: 35798634
The impact of common and rare EGFR mutations in response to EGFR tyrosine kinase inhibitors and platinum-based chemotherapy in patients with non-small cell lung cancer.
Arrieta O, Cardona AF, Corrales L, Campos-Parra AD, Sánchez-Reyes R, Amieva-Rivera E, Rodríguez J, Vargas C, Carranza H, Otero J, Karachaliou N, Astudillo H, Rosell R; CLICaP. Arrieta O, et al. Among authors: otero j. Lung Cancer. 2015 Feb;87(2):169-75. doi: 10.1016/j.lungcan.2014.12.009. Epub 2014 Dec 18. Lung Cancer. 2015. PMID: 25558790
889 results